Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DCC2781	Iy-iy-das	Novel potent noncleavable proteolysis targeting chimeric (PROTAC) for TrkC degradation in metastatic breast cancer cells
DCC2782	Iy-iy-ss-das	Novel potent and cleavable proteolysis targeting chimeric (PROTAC) for TrkC degradation in metastatic breast cancer cells
DCC2783	J-2156 Tfa Salt	Potent and selective agonist of human somatostatin receptor 4 (sst4), reducing mechanosensitivity of peripheral nerve afferents and spinal neurons in an inflammatory pain model
DCC2784	Jak1-in-38a	Novel highly potent JAK1-selective inhibitor, exhibiting excellent selectivity over JAK2, JAK3, and TYK2 (IC 50 : JAK1 0.145 nM; JAK2 2.94 nM; JAK3 2.31 nM; TYK2 8.17 nM)
DCC2785	Jak1-in-b61	Novel JAK1 inhibitor
DCC2786	Jak2-in-7j	Novel selective Jak2 inhibitor, demonstrating a time-dependent knock-down of pSTAT5, a downstream target of Jak2
DCC2787	Jak3-in Tricyclic-1	Novel irreversible selective JAK3 inhibitor through the covalent interaction with a Jak3 active-site cysteine
DCC2788	Jak3-in Tricyclic-2	Novel irreversible selective JAK3 inhibitor through the covalent interaction with a Jak3 active-site cysteine
DCC2789	Jak3-in Tricyclic-3	Novel irreversible selective JAK3 inhibitor through the covalent interaction with a Jak3 active-site cysteine
DCC2790	Jak3-in-4	Novel Selective JAK3 Inhibitor with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket
DCC2791	Jak3-in-5	Novel Selective JAK3 Inhibitor with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket
DCC2792	Jak-in-1	Novel potent JAK1/2/3 inhibitor
DCC2793	Jak-in-3	Novel potent JAK1/3 inhibitor, targeting JAK3 and JAK1 with IC 50 at 3nM and 5nM, respectively
DCC2794	Jami1001a	Novel positive allosteric modulator of AMPA receptor
DCC2795	Jamunone M	Novel anti-triple-negative breast cancer (anti-TNBC) agent with a high selectivity against BC cells over normal human cells, downregulating phosphatidylinositide 3-kinase (PI3K)/Akt pathway by suppressing protein-tyrosine phosphatase 1B (PTP1B) expression
DCC2796	Janelia Fluor 526, Se	Novel fluorogenic yellow fluorescent dye for use in self-labeling tag systems
DCC2797	Jar1.39	Novel mitophagy inducer with therapeutic potential for Parkinson's disease, acting as light chain 3 (LC3) interactors, similar to cardiolipin or ceramide, triggering mitophagy via Pink1/Parkin
DCC2798	jarid1b Demethylase Inhibitor	Novel Inhibitor of Jumonji AT-Rich Interactive Domain 1B (JARID1B) Histone Demethylase
DCC2799	Jasminine	Natural naphthyridine alkaloid
DCC2800	Jasplakinolide	Potent inhibitor of the proliferation of PC3 prostate carcinoma cells
DCC2801	Jbir-22	Natural Inhibitor for Protein−Protein Interaction of the Homodimer of Proteasome Assembly Factor 3
DCC2802	Jbir-59	Natural radical scavenger, inhibiting L-glutamate toxicity in neuronal hybridoma N18-RE-105 cells
DCC2803	Jbp485	Inhibitor of renal transporters OAT1 and OAT3; Antihepatitis agent as a substrate for intestinal PEPT1
DCC2804	Jbp923	Natural anti-inflammatory agent, showing potential for the treatment of inflammatory bowel disease (IBD)
DCC2805	Jbsnf-000567	Metabolite of JBSNF-000088
DCC2806	Jc1-40	Novel RORα activator, diminishing diethylnitrosamine-induced acute liver injury and repressing transcriptional expression of APPs such as CXCL1 and LCN2 in mice
DCC2807	Jcp-170	Novel dose-dependent inhibitor of ABHD6
DCC2808	jcp174-alk	JCP174 analog used for affinity purification of labeled targets
DCC2809	jcp174-ia	Negative control of JCP174
DCC2810	Jcp-265	Novel dose-dependent inhibitor of ABHD6

Novel inhibitors

Customized Consultation X

Your information is safe with us. * Required Fields.